Research progress of novel anti-VEGF therapy in the treatment of neovascular age-related macular degeneration with novel drugs
10.12173/j.issn.2097-4922.202404064
- VernacularTitle:新型抗VEGF疗法在新生血管性年龄相关性黄斑变性中的研究进展
- Author:
Huimin HOU
1
,
2
,
3
;
Xueke CHANG
;
Leying ZHANG
;
Zongming SONG
Author Information
1. 郑州大学人民医院眼科,郑州 450003
2. 河南省人民医院眼科,郑州 450003
3. 河南省立眼科医院眼科,郑州 450003
- Keywords:
Neovascular age-related macular degeneration;
Pathogenesis;
Novel drugs
- From:
China Pharmacist
2024;28(10):268-277
- CountryChina
- Language:Chinese
-
Abstract:
Neovascular age-related macular degeneration (nAMD) is one of the main causes of visual impairment in middle-aged and elderly people,and the incidence of this disease is rising in our country.The imbalance of vascular endothelial growth factor (VEGF) is the main cause of nAMD.In addition,various growth factors other than VEGF,complement system activation,inflammatory factors,autophagy,and many other factors are involved in the pathogenesis of nAMD.Currently,intravitreal injection of anti-VEGF drugs has become the first-line regimen for the treatment of nAMD,but there are still many shortcomings of the current anti-VEGF drugs,such as multiple potential risks of frequent injections,insensitive responses in some patients,and low compliance of the patients,etc.Therefore,the search for novel therapeutic agents has become urgent.This article provides a review of new developments in the study of novel drugs newly marketed and undergoing clinical trials for the treatment of nAMD,with the aim of seeking longer-lasting and better-acting therapeutic regimens,as well as exploring new therapeutic targets,to further inform the advancement of innovation and development of therapeutic strategies for nAMD.
